Overview

A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer

Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the pathological complete tumor response rate.
Phase:
Phase 2
Details
Lead Sponsor:
Hoffmann-La Roche
Collaborator:
Sanofi-Synthélabo (Schweiz) AG
Treatments:
Capecitabine
Oxaliplatin